Abstract:Introduction HIV-1, the primary causative agent of AIDS, remains a formidable and lethal virus globally, claiming the lives of millions over the past four decades since its discovery. Recent research has underscored the potential of HIV-1 protease as a therapeutic target, offering a promising strategy for inhibiting viral replication within the body.Method In light of this, we have curated an extensive database comprising 193 derivatives of Darunavir (DRV), an HIV-1 protease inhibitor. Simultaneously, we have developed a comprehensive set of 3D-QSAR models to elucidate the structure-activity relationships of these 193 derivative inhibitors. Employing various computational simulation techniques, including Comparative Molecular Field Analysis (CoMFA), Comparative Similarity Indices Analysis (CoMSIA), and molecular docking, we have unveiled the fundamental three-dimensional structural features influencing their biological activity.Result Results indicate that the optimal CoMSIA model (Q2 = 0.500, R2ncv = 0.882, R2pred = 0.797) surpasses other models, demonstrating superior predictive capability. Furthermore, docking results suggest that DRV derivatives maintain stable conformations within the binding cavity due to synergistic interactions, such as hydrogen bonding and non-bonded interactions. Drawing insights from the best computational models, we have designed five DRV derivatives with significant HIV-1 protease inhibitory activity through local modification, with theoretical calculations indicating favorable pharmacokinetic properties and synthetic feasibility for the newly proposed molecules.Conclusion It is hoped that the findings and conclusions obtained herein may furnish theoretical underpinning and directional guidance for the design, optimization, and experimental synthesis of DRV derivative compounds for pharmaceutical purposes.

Combined 3D-Qsar Modeling and Molecular Docking Study on Azacycles Ccr5 Antagonists

3D-QSAR Studies of Azacycles CCR5 Antagonists Using CoMFA and CoMSIA Methods

Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.

Identification of Potential CCR5 Inhibitors Through Pharmacophore-Based Virtual Screening, Molecular Dynamics Simulation and Binding Free Energy Analysis

3D-QSAR Modeling, Surflex Docking and Reverse Docking Studies of Diketo-Acid Derivatives as Potent Integrase/Rnase H Inhibitors

Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.

Design, Synthesis and Biological Evaluation of Novel Piperazine Derivatives As CCR5 Antagonists

Combined 3D‐QSAR, Molecular Docking, Molecular Dynamics Simulation, and Binding Free Energy Calculation Studies on the 5‐hydroxy‐2h‐pyridazin‐3‐one Derivatives As HCV NS5B Polymerase Inhibitors

Molecular Docking and 3D-QSAR Research of Diaryltriazines Derivatives as HIV-1 Reverse Transcriptase Inhibitors

Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly

3D-Qsar and Docking Studies on Piperidine-Substituted Diarylpyrimidine Analogues As Hiv-1 Reverse Transcriptase Inhibitors

Design, Synthesis, and Biological Evaluation of Novel Piperidine-4-carboxamide Derivatives As Potent CCR5 Inhibitors

Combination of 2D and 3D-QSAR Studies on DAPY and DANA Derivatives As Potent HIV-1 NNRTIs

Combined 3D-QSAR, Molecular Docking and Molecular Dynamics Study on the Benzimidazole Inhibitors Targeting HCV NS5B Polymerase

Design, Synthesis, and Biological Evaluation of Novel 2-Methylpiperazine Derivatives As Potent CCR5 Antagonists.

Design, Synthesis, and Biological Activity of Novel Octahydro-1H-pyrrolo[3,2-c]pyridine Derivatives As C-C Chemokine Receptor Type 5 (CCR5) Antagonists

Docking-based CoMFA and CoMSIA Study of Azaindole Carboxylic Acid Derivatives As Promising HIV-1 Integrase Inhibitors.

Receptor- and Ligand-Based 3D-QSAR Study for a Series of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.

Structure-Based Design of 1-Heteroaryl-1,3-propanediamine Derivatives As a Novel Series of CC-Chemokine Receptor 5 Antagonists.

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

3D-QSAR for HIV-1 reverse transcriptase inhibitors